Search

Displaying results 1431 - 1440 of 10000 in total
  1. Target

    Interleukin-21 receptor

    go.drugbank.com/bio_entities/BE0010657
    TargetHumans

    This is a receptor for interleukin-21

    Polypeptides: Interleukin-21 receptorSynonyms: IL-21 receptor, Novel interleukin receptor
  2. Target

    Neuromedin-B receptor

    go.drugbank.com/bio_entities/BE0013104
    TargetHumans

    Receptor for neuromedin-B (PubMed:1655761). … Plays a role in CSF1-induced proliferation of osteoclast precursors by contributing to the positive regulation of the expression of the CSF1 receptor CSF1R (By similarity)

    Polypeptides: Neuromedin-B receptorSynonyms: Neuromedin-B-preferring bombesin receptor
  3. Target

    Interleukin-23 receptor

    go.drugbank.com/bio_entities/BE0015564
    TargetHumans

    Associates with IL12RB1 to form the interleukin-23 receptor.

    Polypeptides: Interleukin-23 receptorSynonyms: IL-23 receptor
  4. Target

    Discoidin domain receptor

    go.drugbank.com/bio_entities/BE0027487
    TargetHumans

    It functions as a cell surface receptor for fibrillar collagen and regulates cell differentiation, remodeling of the extracellular matrix, cell migration and cell proliferation. … Regulates remodeling of the extracellular matrix by up-regulation of the collagenases MMP1, MMP2 and MMP13, and thereby facilitates cell migration and tumor cell invasion.

    Polypeptides: Discoidin domain-containing receptor 2, Epithelial discoidin domain-containing receptor 1Synonyms: Discoidin domain receptor 2, Discoidin receptor tyrosine kinase
  5. Target

    Interleukin-2 receptor

    go.drugbank.com/bio_entities/BE0027978
    TargetHumans

    Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2. … Receptor for interleukin-2. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity.

    Polypeptides: Cytokine receptor common subunit gamma, Interleukin-2 receptor subunit alphaSynonyms: IL-2 receptor subunit gamma, IL-2 receptor subunit alpha
  6. Drug

    Tiratricol

    go.drugbank.com/drugs/DB03604
    ApprovedInvestigational

    [A274073] Tiratricol is currently being investigated in US clinical trials. … Tiratricol is an analogue and active metabolite of the thyroid hormone triiodothyronine (T3).

  7. Drug

    Atoltivimab

    go.drugbank.com/drugs/DB15898
    ApprovedInvestigational

    [A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection. … [A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high

  8. Drug

    Ixazomib

    go.drugbank.com/drugs/DB09570
    ApprovedInvestigational

    [A7948] More than 99% of the drug compound is the R-enantiomer.[A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US. … Ixazomib is a reversible proteasome inhibitor. Because it is a modified peptide boronic acid with one chiral center,[A264329] it is considered a boronate proteasome inhibitor.

  9. Drug

    Maraviroc

    go.drugbank.com/drugs/DB04835
    ApprovedInvestigational

    Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the … It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007.

    Categories: CCR5 Receptor Antagonists, CCR5 Co-receptor Antagonist
  10. Drug

    Vayarin

    go.drugbank.com/drugs/DB09328
    Approved

    Vayarin is an orally administered prescription medical food for the clinical dietary management of complex lipid imbalances thought to be associated with ADHD. … A slow response time of 12 weeks is an impediment to successful management of ADHD as only 41.6% of subjects prescribed Vayarin remained compliant for the duration of the study.